Phase 4 N=100 Weight Loss Aid in an Exposed Population
Polybrominated Biphenyl Poisoning
Primary: Weight — 91.3; 92.3; 88.6; 87.4 kilograms (kg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=28 Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama
Toxic Effect of Other Corrosive Organic Compounds
Primary: Percent Change From Baseline for Total PCB Levels — 92; 96 % of baseline total PCBs
Early Phase 1 N=8 Benzo[a]Pyrene Ultralow Dose-Response Study
Environmental Exposure
Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma
Early Phase 1 N=7 Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet
Environmental Exposure
Primary: Peak Plasma Concentration of 14C-BaP Cmax — 3.69; 1.67; 0.68 fg [14C]-BaP/mL plasma
Early Phase 1 N=8 Ultralow Dose PAH Binary Mixture Study
Environmental Exposure
Primary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma
N/A N=10 Phthalate and Bisphenol Exposure During Minipuberty
Phthalate Exposure · Bisphenol Exposure
Primary: Log Signal Intensity of Bisphenol A (BPA) in Child Urine Samples — 0.00; 5.43 Log(Arbitrary Units)
Phase 3 N=12 Betaine and Peroxisome Biogenesis Disorders
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio
N/A N=102 European Survey: Risk of Cyanide Poisoning in Smoke Inhalation
Smoke Inhalation Patients
Primary: Overall Survival After 24 Hours — 96 participants
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
N/A N=20 Bisphenol A in Saliva and Urine Related to Placement of Dental Composites
Dental Polymer Based Filling Material
Primary: Concentration of Bisphenol A in Saliva — 0.25 ng/ml — p=<0.05
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
N/A N=50 BPD Saturation TARgeting
Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Chronic Lung Disease
Primary: Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time — 2.2; 1.2 IH events per 8 hours of monitoring time
N/A N=113 Composites and Urinary Bisphenol-A Study
Dental Caries
Primary: Change in Urinary Bisphenol A Level (BPA) From Baseline to 6 Months — 0.29 ng/mL — p=0.58
Phase 4 N=21 Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
Acetaminophen Toxicity
Primary: Rise in Plasma Transaminases: Proportion of Responders. — 6; 8 Participants — p=0.59
N/A N=10 Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H
End Stage Renal Disease
Primary: BPA Level Following 2 Months of Dialysis — 9.76; 1.55 ng/mL — p=0.05
Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
Phase 2 N=170 Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants
Environmental Carcinogenesis
Primary: Sulforaphane Bioavailability Measured in Sequential 12-Hour Urine Samples — 24.8; 11.0; 4.3 micromoles/24 hours — p=<0.001
Phase 4 N=60 A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
Arsenic Metabolites Measured in Urine
Primary: Change in Urinary % Monomethyl Arsenic — 2.4; 0.24; -0.06; -3.2 percentage of total urinary arsenic
Phase 1 N=6 Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2
Healthy Volunteers
Primary: Absolute Bioavailability of PBT2 (F%) — 15.936 percentage of absolute bioavailability
Phase 2 N=21 A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Primary: The Number of Participants With Treatment Emergent Adverse Events (All TEAEs). — 5; 5; 0 Participants
Phase 3 N=13 Vitamin B6 Effects for Women Taking Birth Control Pills
Vitamin B6 Deficiency
Primary: Total Remethylation of Homocysteine — 6.07; 5.63 micromol/(kg x hr) — p=0.20
Phase 4 N=20 PFAS Exposure and Immune Response to Vaccination in Adults
Innate Inflammatory Response · Vaccination · Diphtheria
Primary: Change in Tetanus-diphtheria Specific IgG by PFNA Exposure Category — 3.54; 3.39; 2.44; 2.43 log2(fold change) — p=.85
Phase 2 N=32 Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
Botulism
Primary: Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration (NAC) — .844; .938; .875; .906 proportion of participants
N/A N=256 Analysis of BPD in Premature Infants With Typical Imaging Changes
Bronchopulmonary Dysplasia
Primary: Mortality — 17; 7 Participants
Phase 3 N=750 Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine
Poliomyelitis
Primary: Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity — 187; 179; 175; 149 Participants
N/A N=187 GER Poses a Potential Risk for Late Complications of BPD
Gastroesophageal Reflux · Bronchopulmonary Dysplasia
Primary: the Late Complications of BPD Infants — 57; 45; 30; 4 Participants
Phase 2 N=109 Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington Disease
Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants